autologous anti-CD3/anti-EGFR bispecific antibody armed peripheral blood mononuclear cells

A preparation of autologous peripheral blood mononuclear cells (PBMCs) in which T lymphocytes are coated with a bispecific antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor (EGFR; HER1; ErbB1) and the T-cell surface antigen CD3 and activated ex vivo, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, the autologous anti-CD3/anti-EGFR bispecific antibody armed PBMCs target, bind to and selectively cross-link CD3-expressing T cells and EGFR-expressing tumor cells. This results in the activation of cytotoxic T lymphocytes (CTLs) and selective cytotoxicity towards the EGFR-expressing tumor cells. EGFR, a receptor tyrosine kinase, is overexpressed on the surfaces of various tumor cell types.